Glioblastoma Treatment by Systemic Actinium-225 alpha-particle Dendrimer-radioconjugates is Improved by Chemotherapy.

A study published in Cancer Weekly discusses the potential of using systemic actinium-225 radiopharmaceutical therapy to treat glioblastoma, a type of brain tumor. The study found that dendrimer-radioconjugates labeled with actinium-225 improved survival in mice with glioblastoma, especially when administered after chemotherapy. The therapy showed promise in inhibiting the growth of glioblastoma cells and prolonging survival without causing notable toxicities. The preprint has not yet been peer-reviewed, and more information can be found on biorxiv.org. [Extracted from the article]